Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4415058> ?p ?o }
Showing triples 1 to 76 of
76
with 100 triples per page.
- Q4415058 subject Q18706655.
- Q4415058 subject Q22570441.
- Q4415058 subject Q7336348.
- Q4415058 subject Q8418429.
- Q4415058 subject Q8672733.
- Q4415058 abstract "Semax is a drug produced and prescribed mostly in Russia and Ukraine for a broad range of conditions but predominantly for its purported nootropic, neuroprotective, and neurogenic/neurorestorative properties. It is a heptapeptide, synthetic analog of a fragment of adrenocorticotropic hormone (ACTH), ACTH (4-10), of the following structure: Met-Glu-His-Phe-Pro-Gly-Pro. Semax has not been evaluated by the U.S. FDA. It is unscheduled in the U.S. and legal to import by private citizens for personal use.Semax has undergone extensive study in Russia and is on the Russian List of Vital & Essential Drugs approved by the Russian Federation government on December 7, 2011. Medical uses for Semax include treatment of stroke, transient ischemic attack, memory and cognitive disorders, peptic ulcers, optic nerve disease, and to boost the immune system.In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor TrkB in the hippocampus, and rapidly activates serotonergic and dopaminergic brain systems. In accordance, it has been found to produce antidepressant-like and anxiolytic-like effects, attenuate the behavioral effects of exposure to chronic stress, and potentiate the locomotor activity produced by D-amphetamine. As such, it has been suggested that Semax may be effective in the treatment of depression, as well as in attention deficit hyperactivity disorder (ADHD).Though the exact mechanism of action of Semax is unclear, there is evidence that it may act through melanocortin receptors. Specifically, there is a report of Semax competitively antagonizing the action of the melanocortin receptor full agonist α-melanocyte-stimulating hormone (α-MSH) at the MC4 and MC5 receptors in both in vitro and in vivo experimental conditions, indicating that it may act as an antagonist (or partial agonist) of these receptors. Semax did not antagonize α-MSH at the MC3 receptor, though this receptor could still be a target of the drug. As for the MC1 and MC2 receptors, they were not assayed. In addition to actions at receptors, Semax, as well as a related peptide drug, Selank, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, and this action may also be involved in their effects.".
- Q4415058 atcPrefix "N06BX".
- Q4415058 casNumber "4037-01-8".
- Q4415058 casSupplemental "80714-61-0 (free base)".
- Q4415058 iupacName "L-Methionyl-L-α-glutamylhistidyl-L-phenylalanyl-L-prolylglycyl-L-proline".
- Q4415058 pubchem "122178".
- Q4415058 thumbnail Semax_structure.png?width=300.
- Q4415058 wikiPageWikiLink Q1059.
- Q4415058 wikiPageWikiLink Q12202.
- Q4415058 wikiPageWikiLink Q14863330.
- Q4415058 wikiPageWikiLink Q14897782.
- Q4415058 wikiPageWikiLink Q14909766.
- Q4415058 wikiPageWikiLink Q159.
- Q4415058 wikiPageWikiLink Q1706418.
- Q4415058 wikiPageWikiLink Q172847.
- Q4415058 wikiPageWikiLink Q172941.
- Q4415058 wikiPageWikiLink Q174211.
- Q4415058 wikiPageWikiLink Q18028916.
- Q4415058 wikiPageWikiLink Q18028918.
- Q4415058 wikiPageWikiLink Q18028921.
- Q4415058 wikiPageWikiLink Q18028923.
- Q4415058 wikiPageWikiLink Q181923.
- Q4415058 wikiPageWikiLink Q185690.
- Q4415058 wikiPageWikiLink Q186029.
- Q4415058 wikiPageWikiLink Q18706655.
- Q4415058 wikiPageWikiLink Q1981368.
- Q4415058 wikiPageWikiLink Q204711.
- Q4415058 wikiPageWikiLink Q212.
- Q4415058 wikiPageWikiLink Q22570441.
- Q4415058 wikiPageWikiLink Q26972.
- Q4415058 wikiPageWikiLink Q285982.
- Q4415058 wikiPageWikiLink Q30.
- Q4415058 wikiPageWikiLink Q3065932.
- Q4415058 wikiPageWikiLink Q3072083.
- Q4415058 wikiPageWikiLink Q325101.
- Q4415058 wikiPageWikiLink Q3271540.
- Q4415058 wikiPageWikiLink Q3305232.
- Q4415058 wikiPageWikiLink Q389934.
- Q4415058 wikiPageWikiLink Q410943.
- Q4415058 wikiPageWikiLink Q4340209.
- Q4415058 wikiPageWikiLink Q4590759.
- Q4415058 wikiPageWikiLink Q461076.
- Q4415058 wikiPageWikiLink Q4734908.
- Q4415058 wikiPageWikiLink Q48360.
- Q4415058 wikiPageWikiLink Q485014.
- Q4415058 wikiPageWikiLink Q5810370.
- Q4415058 wikiPageWikiLink Q593958.
- Q4415058 wikiPageWikiLink Q62903.
- Q4415058 wikiPageWikiLink Q7336348.
- Q4415058 wikiPageWikiLink Q742487.
- Q4415058 wikiPageWikiLink Q76560.
- Q4415058 wikiPageWikiLink Q770260.
- Q4415058 wikiPageWikiLink Q8047.
- Q4415058 wikiPageWikiLink Q8386.
- Q4415058 wikiPageWikiLink Q8418429.
- Q4415058 wikiPageWikiLink Q8672733.
- Q4415058 wikiPageWikiLink Q909393.
- Q4415058 wikiPageWikiLink Q9404.
- Q4415058 atcPrefix "N06BX".
- Q4415058 casNumber "4037-01-08".
- Q4415058 casSupplemental "80714".
- Q4415058 iupacName "L-Methionyl-L-α-glutamylhistidyl-L-phenylalanyl-L-prolylglycyl-L-proline".
- Q4415058 pubchem "122178".
- Q4415058 type ChemicalSubstance.
- Q4415058 type Drug.
- Q4415058 type ChemicalObject.
- Q4415058 type Thing.
- Q4415058 type Q8386.
- Q4415058 comment "Semax is a drug produced and prescribed mostly in Russia and Ukraine for a broad range of conditions but predominantly for its purported nootropic, neuroprotective, and neurogenic/neurorestorative properties. It is a heptapeptide, synthetic analog of a fragment of adrenocorticotropic hormone (ACTH), ACTH (4-10), of the following structure: Met-Glu-His-Phe-Pro-Gly-Pro. Semax has not been evaluated by the U.S. FDA. It is unscheduled in the U.S.".
- Q4415058 label "Semax".
- Q4415058 depiction Semax_structure.png.